Next Article in Journal
Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?
Next Article in Special Issue
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Previous Article in Journal
Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
Previous Article in Special Issue
Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Cancers 2019, 11(3), 282; https://doi.org/10.3390/cancers11030282

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients

1
Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto 602-0841, Japan
2
Department of Internal Medicine, Self Defense Forces Fukuoka Hospital, Fukuoka 816-0826, Japan
*
Author to whom correspondence should be addressed.
Received: 20 February 2019 / Accepted: 25 February 2019 / Published: 27 February 2019
(This article belongs to the Special Issue Epidermal Growth Factor Receptor Signaling in Cancer)
Full-Text   |   PDF [1907 KB, uploaded 1 March 2019]   |  

Abstract

Previously, we reported that nicotine reduces erlotinib sensitivity in a xenograft model of PC9, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-sensitive non-small-cell lung cancer cell line. The present study examined whether smoking induces erlotinib resistance in vitro. We assessed resistance to EGFR-TKIs by treating cancer cell lines with erlotinib, afatinib, or osimertinib, and serum collected from smokers within 30 min of smoking and that from a non-smoker as a control. We also assessed erlotinib resistance by treating PC9 cells exposed to serum from a smoker or a non-smoker, or serum from an erlotinib user. Treatment of the cancer cell lines with serum from smokers induced significant erlotinib resistance, compared with the control (p < 0.05). Furthermore, serum samples with a high concentration of cotinine (a nicotine exposure indicator) demonstrated stronger erlotinib resistance than those with low concentrations. Similar to the observations with erlotinib treatment of cell lines, the analysis of serum from erlotinib users revealed that smokers demonstrated significantly reduced sensitivity to erlotinib (p < 0.001). In conclusion, our present results support the hypothesis that smoking contributes to resistance to erlotinib therapy in non-small-cell lung cancer. View Full-Text
Keywords: cotinine; nicotine; non-small-cell lung cancer (NSCLC); EGFR; erlotinib resistance cotinine; nicotine; non-small-cell lung cancer (NSCLC); EGFR; erlotinib resistance
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Imabayashi, T.; Uchino, J.; Osoreda, H.; Tanimura, K.; Chihara, Y.; Tamiya, N.; Kaneko, Y.; Yamada, T.; Takayama, K. Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. Cancers 2019, 11, 282.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top